Magic Mushrooms Could Be the Next Investment Trend

“The world is moving so fast these days that the man who says it can’t be done is generally interrupted by someone doing it.” ― Elbert Hubbard

A new medical development is sweeping the country…

Some may see it as controversial – but the studies don’t lie.

It’s effective.

So effective, in fact, that the FDA has just fast-tracked approval for research…

Meaning that it is aiming to gain a major stake in a key healthcare market that is on track to hit $260 billion in the next six years.

And one company, in particular, is making lots of right moves.

In the last 13 months, Champignon Brands (CN:SHRM;OTC:SHRMF) has taken a potential wonder drug from concept to product production for medical research. It then went public as a company and gained controlling ownership of a leading medical treatment clinic.

The name of this potential wonder drug is psilocybin, a natural psychedelic compound found in mushrooms, and it could very well end up saving the life of someone you love.

Interest in psilocybin has exploded recently due to its potential to treat depression, post-traumatic stress disorder (PTSD), substance abuse and even to increase mental performance. While currently a controlled drug and mostly illegal, psilocybin has been cleared for medical research in these areas.

This has attracted attention from high-level performers from Silicon Valley to Wall Street.

And amidst all of this hype, one company stands out.

With bold plans to roll out treatment facilities in the U.S. by the end of 2020, Champignon Brands plans to own and control its own product vertical.

Its ambitious goals and potent growth strategy just dropped Champignon Brands directly within the $89 billion dollar a year mental health sector.

A sector whose time has come for disruption.

Describing themselves as a “Healing Optimization Company,” Champignon Brands committed themselves from the start to gain early mover advantage in the sector.

Starting in March 2019, CEO Gareth Birdsall, noticing a rising interest in the psychedelic medical or “microdosing” movement, quickly began building a company focusing on the theme and power players within the industry.

To help “navigate the waters” and attract top-level medical experts along with deal flow, Birdsall put together a board consisting of a top securities lawyer, a cannabis accountant, and two Toronto ex-narcotic officers experienced with decriminalized drugs.

The strategy, rewrite the playbook on what it means to fast-track sector vertical integration by owning, controlling and developing a basket portfolio of production assets and intellectual properties.

To set a base foundation and introduce itself to the market, Champignon Brands (CN:SHRM;OTC:SHRMF) first created Vitality Superteas, a retail e-commerce distributor of teas packed with high-quality mushroom and superfood extracts.

The creation of Vitality Superteas positioned Champignon Brands into the functional mushroom market. A market expected to hit $34 billion dollars in revenue by 2024.